An Observational Study Evaluating Cholesterol Levels in Patients on Cholesterol Lowering Drugs in Jordan and Lebanon (CEPHEUS)
|ClinicalTrials.gov Identifier: NCT01614561|
Recruitment Status : Completed
First Posted : June 8, 2012
Last Update Posted : June 8, 2012
This was a multicenter survey of patients who were on lipid -lowering pharmacological treatment in 2 Levant countries namely Jordan and Lebanon. The purpose is to study the effects of cholesterol lowering drugs on the blood cholesterol levels of patients in Jordan and Lebanon.
Data collected from each patient took place at a single visit. Each participating doctor filled the investigator questionnaire on his/her experience and perception of the management of the hypercholesterolemia of his/her patients. Each doctor was asked to indicate his/her general attitude on the diagnosis of hypercholesterolemia, the existing guidelines and goals and the various treatment options for high cholesterol in blood.
Before being assessed by the investigator, patients recorded, on the patient questionnaire, their awareness of high blood cholesterol , their current lipid-lowering treatment schedule, their understanding of their condition and compliance in taking the medications on time.
The investigators completed a Patient Record Form (PRF) with the patient's basic information, cardiovascular risk factors and the cardiovascular medical history, current lipid lowering drug treatment and the reason for the current therapy.
A blood sample under fasting condition was drawn from each subject. A central laboratory in Jordan received all samples. Every sample was analyzed for its cholesterol blood level, fasting sugar level and hemoglobin A1C levels.
|Condition or disease|
|High Blood Cholesterol|
|Study Type :||Observational|
|Actual Enrollment :||1000 participants|
|Official Title:||CEPHEUS Centralized Pan-Levant Survey on the Undertreatment of Hypercholesterolemia NIS-LT-CRE-2010/01 Version 1.0|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||December 2010|
|Actual Study Completion Date :||December 2010|
- Number and percentage of subjects achieving the LDL-C goals, according to the NCEP ATP III / updated 2004 NCEP ATP III guidelines, in Jordan and Lebanon [ Time Frame: 5 months- One visit only, no follow up visits ]
- Number and percentage of subjects achieving LDL-C goals according to the NCEP ATP III / 2004 updated NCEP ATP III guidelines, for several subject subsets [ Time Frame: 5 months- One visit only, no follow up visits ]
- Number and percentage of subjects achieving the LDL-C goals, according to the Third Joint European Task Force guidelines, overall and for several subject subsets [ Time Frame: 5 months- One visit only, no follow up visits ]
- Number and percentage of subjects achieving the non HDL-C goals according to the NCEP ATP III / updated 2004 NCEP ATP III / national guidelines (<130 mg/dL), in the following sub-population: patients with fasting triglycerides >200 mg/dL. [ Time Frame: 5 months- One visit only, no follow up visits ]
- Achievement of LDL-C goals, according to the Third Joint European Task Force TJETF / NCEP ATP III / 2004 updated NCEP ATP III guidelines, and patient and physician variables. Assessed using Multivariate logistic regression mode [ Time Frame: 5 months- One visit only, no follow up visits ]
- Physician characteristics associated with the allocation of treatment regimen. [ Time Frame: 5 months- One visit only, no follow up visits ]
Biospecimen Retention: None Retained
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01614561
|Principal Investigator:||Ayman Hammoudeh, MD||Istishari Hospital Amman|